Physician profile
Jane Chandy Abraham
NPI 1356761522
$10,116.21
in general payments reported to CMS, 2019-2025
51 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $977 · 2021: $1,056 · 2022: $1,317 · 2023: $1,545 · 2024: $2,069 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,384.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,380.26 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,173.47 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $908.12 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $800.01 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $645.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.22 | 2019-2025 | Jardiance, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $346.70 | 2019-2023 | Xarelto |
| Amgen INC. | $307.65 | 2021-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $297.93 | 2021-2025 | |
| Abbott Laboratories | $260.68 | 2019-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $238.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $225.12 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $214.48 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $214.34 | 2020-2021 | |
| Axsome Therapeutics, INC. | $199.49 | 2024-2025 | Auvelity |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.